TACE combined with regorafenib with or without anti-PD-1 therapy for advanced HCC after targeted therapy failure: a multicenter real-world study. - Li Y; Yuan H; Yao QJ; Geng X; Xu F; Fan W; Wu G; Cao GS; Song HY; Hu HT (Frontiers in oncology, 2025)